Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. (Q37160109)
Jump to navigation
Jump to search
scientific article published on 02 July 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. |
scientific article published on 02 July 2016 |
Statements
1 reference
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. (English)
1 reference
Giuseppe Viale
1 reference
Aron Goldhirsch
1 reference
Meredith M Regan
1 reference
Carmen Criscitiello
1 reference
Karen N Price
1 reference
Giancarlo Pruneri
1 reference
Roswitha Kammler
1 reference
Thomas Ruhstaller
1 reference
Kathryn P Gray
1 reference
István Láng
1 reference
Lorenzo Gianni
1 reference
Giuseppe Cancello
1 reference
Richard D Gelber
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference